VBI Vaccines Inc. (VBIV)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
VBI Vaccines Inc. (VBIV) trades at $0.07 with AI Score 61/100 (Grade B+). VBI Vaccines Inc. is a biopharmaceutical company specializing in the development and commercialization of vaccines for infectious diseases and immuno-oncology. Market cap: $1.87M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for VBIV: VBIV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VBIV against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VBIV: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →VBI Vaccines Inc. (VBIV) Healthcare & Pipeline Overview
VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, leveraging its enveloped virus-like particle (eVLP) platform. The company's lead product, Sci-B-Vac, targets hepatitis B, while its pipeline includes vaccine candidates for glioblastoma, cytomegalovirus, and coronaviruses.
What Is the Investment Thesis for VBIV?
VBI Vaccines Inc. presents a compelling investment thesis centered on its innovative eVLP vaccine platform and diverse pipeline targeting infectious diseases and immuno-oncology. Key value drivers include the continued commercialization of Sci-B-Vac, the advancement of VBI-2601 (BRII-179) for chronic HBV infection, and the progress of its eVLP-based vaccine candidates, VBI-1901 for glioblastoma and VBI-1501 for cytomegalovirus. Growth catalysts include positive clinical trial results for its pipeline candidates, strategic partnerships, and potential regulatory approvals. However, the company's negative profit margin of -1069.3% and gross margin of -67.0% highlight significant financial risks. The company's high beta of 2.17 indicates high volatility relative to the market.
Based on FMP financials and quantitative analysis
VBIV Key Highlights
- VBI Vaccines Inc. develops and sells vaccines for infectious diseases and immuno-oncology.
- Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine, is the company's lead commercial product.
- The company's eVLP platform is used to develop vaccine candidates for glioblastoma (VBI-1901) and cytomegalovirus (VBI-1501).
- VBI is developing VBI-2601 (BRII-179) as an immunotherapeutic candidate for chronic HBV infection.
- The company has collaboration agreements with Brii Biosciences Limited and GlaxoSmithKline Biologicals S.A.
Who Are VBIV's Competitors?
VBIV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GSK GSK plc | $53.20 | -0.87% | $106.54B | 61 |
| MRNA Moderna, Inc. | $81.41 | +2.06% | $32.30B | — |
| PFE Pfizer Inc. | $23.73 | -2.43% | $135.25B | 64 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VBIV's Key Strengths?
- Proprietary eVLP platform technology.
- Commercialized hepatitis B vaccine (Sci-B-Vac).
- Strategic collaborations with Brii Biosciences and GlaxoSmithKline.
- Diverse pipeline of vaccine candidates targeting infectious diseases and immuno-oncology.
What Are VBIV's Weaknesses?
- Negative profit margin and gross margin.
- Reliance on collaborations for development and commercialization.
- Limited financial resources compared to larger pharmaceutical companies.
- High beta indicates high volatility.
What Could Drive VBIV Stock Higher?
- Clinical trial results for VBI-2601 (BRII-179) in chronic HBV infection.
- Clinical trial results for VBI-1901 in glioblastoma.
- Regulatory approvals for Sci-B-Vac in new markets.
- Progress in the development of coronavirus vaccine candidates.
- Expansion of collaborations with pharmaceutical and biotechnology companies.
What Are the Key Risks for VBIV?
- Financial-distress signal — its Altman Z-Score of -14.88 sits in the distress zone (elevated bankruptcy risk).
- Regulatory setbacks and clinical trial failures.
- Competition from established pharmaceutical companies.
- Patent expiration and generic competition.
- Financial risks and need for additional funding.
- Dependence on collaborations for development and commercialization.
What Are the Growth Opportunities for VBIV?
- Advancement of VBI-2601 (BRII-179) for Chronic HBV Infection: VBI-2601, in collaboration with Brii Biosciences, targets the large market of chronic HBV infection. Positive clinical trial results and regulatory approvals could drive significant revenue growth. The global market for HBV therapeutics is projected to reach billions of dollars, offering a substantial opportunity for VBI. The ongoing collaboration with Brii Biosciences provides financial and developmental support for this program.
- Development of VBI-1901 for Glioblastoma: VBI-1901, a glioblastoma vaccine immunotherapeutic, addresses a critical unmet need in the treatment of this aggressive brain cancer. The glioblastoma market is expected to grow, driven by the aging population and advancements in cancer immunotherapy. Positive Phase I/IIa clinical study results could lead to further development and potential commercialization, creating a significant growth opportunity for VBI. This program leverages VBI's eVLP platform to stimulate an immune response against glioblastoma cells.
- Expansion of Sci-B-Vac Market Share: Sci-B-Vac, VBI's prophylactic hepatitis B vaccine, has the potential to expand its market share globally. Hepatitis B remains a significant public health concern, particularly in developing countries. By increasing production capacity, securing additional regulatory approvals, and expanding its distribution network, VBI can capitalize on the growing demand for HBV vaccines. This growth opportunity is supported by the established safety and efficacy profile of Sci-B-Vac.
- Development of Coronavirus Vaccine Candidates: VBI's coronavirus vaccine candidates, including VBI-2902 and VBI-2901, target COVID-19 and other coronaviruses. The ongoing COVID-19 pandemic and the potential for future coronavirus outbreaks create a significant market opportunity for effective vaccines. Collaborations with the National Research Council of Canada and CEPI enhance VBI's ability to develop and commercialize these vaccine candidates. Success in this area could generate substantial revenue and establish VBI as a key player in the coronavirus vaccine market.
- Licensing of Vaccine Platforms and Products: VBI's strategy includes licensing its vaccine platforms and products to pharmaceutical and biotechnology companies. This approach allows VBI to generate revenue through upfront payments, milestone payments, and royalties, while leveraging the resources and expertise of its partners. By actively seeking licensing agreements, VBI can diversify its revenue streams and accelerate the development and commercialization of its vaccine technologies. This strategy is particularly attractive for vaccine candidates targeting niche markets or requiring significant investment in manufacturing and distribution.
What Opportunities Does VBIV Have?
- Advancement of VBI-2601 for chronic HBV infection.
- Development of VBI-1901 for glioblastoma.
- Expansion of Sci-B-Vac market share.
- Development of coronavirus vaccine candidates.
What Threats Does VBIV Face?
- Regulatory hurdles and clinical trial failures.
- Competition from established pharmaceutical companies.
- Patent expiration and generic competition.
- Financial risks and need for additional funding.
What Are VBIV's Competitive Advantages?
- Proprietary eVLP platform technology enables the development of novel vaccine candidates.
- Established commercial presence with Sci-B-Vac, a prophylactic hepatitis B vaccine.
- Strategic collaborations with Brii Biosciences Limited and GlaxoSmithKline Biologicals S.A.
- Intellectual property protection for its vaccine candidates and platform technologies.
What Does VBIV Do?
VBI Vaccines Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing and commercializing vaccines for the treatment of infectious diseases and immuno-oncology. Founded with the mission of addressing unmet needs in global health through innovative vaccine technologies, VBI has evolved into a company with a diverse pipeline of vaccine candidates. The company's flagship product is Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. In addition to Sci-B-Vac, VBI is actively developing VBI-2601 (BRII-179), an immunotherapeutic candidate aimed at treating chronic HBV infection, in collaboration with Brii Biosciences. VBI's enveloped virus-like particle (eVLP) platform technology is central to its vaccine development efforts, enabling the creation of vaccines that mimic the natural presentation of viruses to the human immune system. This platform is being utilized to develop vaccine candidates such as VBI-1901, a glioblastoma vaccine immunotherapeutic currently in Phase I/IIa clinical study, and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. Furthermore, VBI is engaged in the development of coronavirus vaccine candidates, including VBI-2902 and VBI-2901, and collaborates with organizations like the National Research Council of Canada and the Coalition for Epidemic Preparedness Innovations (CEPI) to advance these efforts. Formerly known as SciVac Therapeutics Inc., the company rebranded as VBI Vaccines Inc. in May 2016 to reflect its broader focus on vaccine development across multiple therapeutic areas.
What Products and Services Does VBIV Offer?
- Develop and sell vaccines for infectious diseases.
- Develop and sell vaccines for immuno-oncology.
- Offer Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine.
- Develop VBI-2601 (BRII-179) for chronic HBV infection.
- Utilize the eVLP platform to develop vaccine candidates.
- Develop VBI-1901, a glioblastoma vaccine immunotherapeutic candidate.
- Develop VBI-1501, a prophylactic cytomegalovirus vaccine candidate.
- Develop coronavirus vaccine candidates, such as VBI-2902 and VBI-2901.
How Does VBIV Make Money?
- Develop and commercialize vaccines for infectious diseases and immuno-oncology.
- Generate revenue through the sale of Sci-B-Vac and potential future vaccine products.
- Collaborate with pharmaceutical and biotechnology companies to develop and commercialize vaccine candidates.
- License vaccine platforms and products to generate revenue through upfront payments, milestone payments, and royalties.
What Industry Does VBIV Operate In?
VBI Vaccines Inc. operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant market potential. The global vaccine market is experiencing growth, driven by increasing awareness of preventative healthcare, rising incidence of infectious diseases, and advancements in vaccine technologies. VBI competes with established pharmaceutical companies and other biotechnology firms in the development and commercialization of vaccines. The company's eVLP platform provides a competitive advantage, enabling the development of novel vaccine candidates that mimic natural virus presentation.
Who Are VBIV's Key Customers?
- Individuals seeking protection against hepatitis B through vaccination.
- Patients with chronic HBV infection seeking immunotherapeutic treatment.
- Patients with glioblastoma seeking vaccine immunotherapeutic treatment.
- Individuals seeking protection against cytomegalovirus through vaccination.
- Pharmaceutical and biotechnology companies interested in licensing VBI's vaccine platforms and products.
FY2026 estForward Outlook
Wall Street analysts project VBI Vaccines Inc. revenue of about $58.8M for fiscal 2026, with EPS near $-0.23.
VBIV Valuation & Market Position
With a $1.87M market cap, VBI Vaccines Inc. sits in the micro-cap segment of the market. Relative to its peer group, VBIV's quantitative score of 61/100 is roughly in line with the peer average of 71/100.
F-Score 4/9Financial Health
VBI Vaccines Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -14.88 places it in the distress zone, a signal of elevated financial risk.
Company Profile
VBI Vaccines Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Jeffery R. Baxter FCMA. VBIV has traded publicly since 2010.
VBIV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that insiders believe in the potential of VBI Vaccines.
- Community sentiment has shifted positively following announcements regarding new vaccine developments, fostering increased interest among investors.
- VBI's focus on innovative vaccine solutions positions it well in a growing market, appealing to health-conscious investors and institutions alike.
- Recent collaborations with larger pharmaceutical companies enhance credibility and open doors for potential funding and research opportunities.
Bear Case
- Concerns over the competitive landscape in the vaccine sector may dampen investor enthusiasm, as many companies are vying for market share.
- Community sentiment has shown volatility, with mixed opinions on the company's long-term viability and ability to deliver on promises.
- Regulatory challenges in the pharmaceutical industry can create uncertainty, leading some investors to adopt a cautious stance.
- Recent financial reports have raised questions about cash flow sustainability, prompting fears about the company's operational viability in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
VBIV Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Dec 7, 2022
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Nov 7, 2022
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Oct 21, 2022
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Jun 13, 2022
VBIV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VBIV.
Price Targets
Wall Street price target analysis for VBIV.
VBIV MoonshotScore
What does this score mean?
The MoonshotScore rates VBIV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeffery R. Baxter FCMA
Chief Executive Officer
Jeffery R. Baxter is the Chief Executive Officer of VBI Vaccines Inc. He is a Fellow of the Chartered Institute of Management Accountants (FCMA). His background includes extensive experience in the biopharmaceutical industry, with a focus on financial management, strategic planning, and business development. He has held leadership positions at various companies, contributing to their growth and success. His expertise spans across financial operations, corporate strategy, and investor relations.
Track Record: Under Jeffery Baxter's leadership, VBI Vaccines Inc. has focused on advancing its pipeline of vaccine candidates and expanding its collaborations. Key milestones include the continued commercialization of Sci-B-Vac and the progress of VBI-2601 (BRII-179) in clinical development. He has also overseen the development of VBI's eVLP platform and the expansion of its coronavirus vaccine program.
What Investors Ask About VBI Vaccines Inc. (VBIV) — Healthcare
What does VBI Vaccines Inc. do?
VBI Vaccines Inc. is a biopharmaceutical company that develops and sells vaccines for infectious diseases and immuno-oncology. The company's lead product is Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. VBI also develops vaccine candidates using its enveloped virus-like particle (eVLP) platform, including VBI-2601 (BRII-179) for chronic HBV infection, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus. Additionally, VBI is developing coronavirus vaccine candidates and exploring licensing opportunities for its vaccine platforms and products.
What do analysts say about VBIV stock?
Analyst coverage of VBIV stock reflects a focus on the company's pipeline progress and commercial potential. Key valuation metrics include market capitalization and potential revenue from its vaccine candidates. Growth considerations center on clinical trial outcomes, regulatory approvals, and market adoption of its products. Analyst consensus is influenced by the company's ability to execute its development programs and secure strategic partnerships. However, the company's financial performance and market volatility are also factored into analyst ratings.
What are the main risks for VBIV?
The main risks for VBI Vaccines Inc. include regulatory setbacks and clinical trial failures, which could delay or halt the development and commercialization of its vaccine candidates. Competition from established pharmaceutical companies with greater resources and broader product portfolios poses a significant challenge. Patent expiration and generic competition could erode the market share of its products. Financial risks, including the need for additional funding, and dependence on collaborations for development and commercialization also represent key concerns for investors.
How does VBI Vaccines Inc. navigate regulatory approval processes?
VBI Vaccines Inc. navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies such as the FDA and EMA. The company conducts comprehensive preclinical and clinical studies to demonstrate the safety and efficacy of its vaccine candidates. VBI maintains a focus on compliance with Good Manufacturing Practices (GMP) in its manufacturing processes. The company also engages in ongoing communication with regulatory agencies to address any concerns and ensure a smooth approval process. VBI's regulatory strategy is crucial for the successful commercialization of its vaccine products.
How does VBI Vaccines Inc. manage patent expiration risks?
VBI Vaccines Inc. manages patent expiration risks through a comprehensive intellectual property strategy. This includes actively seeking patent protection for its vaccine candidates, platform technologies, and manufacturing processes. The company also focuses on developing new formulations and delivery methods to extend the lifecycle of its products. VBI monitors the competitive landscape and actively defends its intellectual property rights. By proactively managing patent expiration risks, VBI aims to maintain a competitive advantage and maximize the value of its vaccine portfolio.
What are the key factors to evaluate for VBIV?
VBI Vaccines Inc. (VBIV) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does VBIV data refresh on this page?
VBIV prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VBIV's recent stock price performance?
VBI Vaccines Inc. (VBIV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary eVLP platform technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recently available information.
- Analyst opinions and ratings are subject to change.
- Clinical trial outcomes are inherently uncertain.